[Skip to Content]
[Skip to Content Landing]
April 11, 2001

Statins and Fracture Risk

Author Affiliations

Author Affiliations: Department of Biostatistics and Epidemiology, Center for Clinical Epidemiology and Biostatistics, Agency for Healthcare Research and Quality, Rockville, Md; and Center for Education and Research on Therapeutics, University of Pennsylvania School of Medicine, Philadelphia, Pa.

JAMA. 2001;285(14):1888-1889. doi:10.1001/jama.285.14.1888

Loss of bone mass accompanies the aging process and increases risk of fracture, particularly in women. The principal sites of osteoporotic fractures are the forearm, vertebral body, and hip.1 Pharmacological theory2 and in vivo3 and animal4 model observations have suggested that 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors (statins) may increase bone mineral density, raising the hope that these drugs also may be useful in reducing risk of osteoporotic fractures.

First Page Preview View Large
First page PDF preview
First page PDF preview